Madison Conces, MD

GI Medical Oncologist @UHhospitals Seidman Cancer Center @caseccc. Hematology/Oncology & IM trained via @ClevelandClinic. IUSM grad. Tweets are my own.

[Mark Yarchoan @MarkYarchoan]

For decades, NIH-funded scientists studied KRAS when pharma considered it "undruggable." KRAS-targeted therapies like daraxonrasib are the result of decades of federally funded basic science. This is exactly the wrong moment to be cutting federal research funding

[Mark Yarchoan @MarkYarchoan]

The timing could not be worse. At #ASCO2026, we saw #daraxonrasib double survival in #PDAC, a reminder that decades of NIH research investment are paying off. Yet federal research funding is being cut. The biggest victims won't be scientists... They'll be future patients

[Kristen Ciombor @KristenCiombor]

Fantastic educational session happening right now @ASCO on immunotherapy in colorectal cancer. Such thoughtful and brilliant colleagues (Stacey Cohen, Chris Lieu and @KaiKeenShiu) and friends!

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Historic. Daraxonrasib did not come from nowhere. It stands on decades of #NIH & #NCI supported work on RAS biology to tackle one of cancer’s most stubborn “undruggable” targets.
Credit Revolution Medicines for execution and clinical development. We should also credit the public federally funded research ecosystem that made the target, tools, and translational path possible.

[Thor Halfdanarson @OncoThor]

Twice today already at ASCO I have heard presenters say “patients failed treatment”.

Can we please, please stop that?

Treatments fail patients, not the other way around…

[Madison Conces, MD @MadisonConces]

@BHuffmanMD I know @BHuffmanMD !!! 🤞🤞🤞

[Madison Conces, MD @MadisonConces]

Incredibly moving moment. I think there were likely some tears (or almost tears) too! 💪🥹 #ASCOGI

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26

[Anirban Maitra @Aiims1742]

The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al.
A seminal #ASCO26 plenary!
https://t.co/ub099PSsOq

[Dr. Cathy Eng @CathyEngMD]

I just learned #cancer #surgical icon of the #nonoperativemanagement approach to #rectalcancer Dr. Angelita Habr-Gama just passed away today at the age of 93. She was AMAZING! She has changed our views on the necessity of surgery in the setting of cCR. #groundbreaking #cancerresearch #originaldisruptor

[Dr. Cathy Eng @CathyEngMD]

Our #ASCO26: #BREAKWATER #PFS and #OS results with the FOLFIRI chemo backbone in #BRAFV600E MT #colorectalcancer.
👉PFS: Median 15.2 vs. 8.3M, HR = 0.44
👉 OS: Median NR vs. 20.3M, HR = 0.53
We are so glad to provide another option for our pts!
@PfizerOncMed @ASCO #cancer #cancerresearch @OncoAlert

[Madison Conces, MD @MadisonConces]

Come check out a phase I study of a novel ADC (BC3195) targeting cadherin-3 (CDH-3) at poster 172! #ASCO26

Also - find yourself colleagues that bring you grilled cheese and caffeine during your 2nd poster session of the day! ☺️😋 #readytogo @LumishMelissa @lauren_henke

[Madison Conces, MD @MadisonConces]

@AgrimaMianMD @ASCO @ConquerCancerFd @AACR Congratulations @AgrimaMianMD ! 🎉👏

[Madison Conces, MD @MadisonConces]

@lungoncdoc @OncoAdvLukas @cancerGRACE @ASCO @ConquerCancerFd Congratulations @lungoncdoc ! 🎉

[Charles Jiang MD, MPH @CharlesJiangMD]

1/A few years into my career, I started a quiet game at #ASCO. I would stop at a poster, read the title, and try to work out what the team actually had going for them. Do this for the past 5 years and a pattern appears:

[Mukund Iyengar @mukundiyngr]

Cancer survival in the U.S. just crossed 70%.

It was 63% in the 1990s.
That gap = 4.8M people alive today.

This one chart captures survival gains across 29 cancer types.

The wins are real.
So is the unfinished work.

▪️CML: 31% → 72%
▪️Multiple myeloma: 32% → 62%
▫️Kidney: 59% → 82%
▫️Metastatic melanoma: 16% → 35%
▫️Childhood ALL: 80% → 92%

But some cancers barely moved.

Cervical cancer outcomes actually worsened.

None of this is abstract progress, though.
These are birthdays, grandkids, and years of life returned.

This is what funded science does.

Next time someone asks if cancer research works, show them this (full) chart.

- - - - -
Source: ACS Cancer Statistics 2026 · SEER · 𝘷𝘪𝘢 @Jori_health
- - - - -

[Eric Topol @EricTopol]

The worst cancers with respect to lethality get the least federal funding support
https://t.co/uCJXYgpB3c

[Mukund Iyengar @mukundiyngr]

Every cancer drug you prescribe today
was once an NIH grant nobody noticed.

Pharma celebrates launches.

Few notice the 20–40 year runway behind that.

Gleevec took 41 years from NIH-funded discovery of the Philadelphia chromosome → FDA approval.

Behind every “breakthrough” sits a graveyard of failed attempts that made it possible.

Cut that lineage today,
the next Gleevec doesn’t arrive in 2067.

Funded science matters.

If someone says NIH funded science is inefficient,
show them this.

- - - - -
Source: NIH RePORTER · FDA · via @Jori_health
- - - - -

[Alok Khorana, MD @aakonc]

Early phase daraxonrasib trial data out. Safety study (with high grade 3 AEs). For those looking for some idea of response, appears to be about 30-35%, median duration 8mo in previously treated PDAC

[Nicholas Fabiano, MD @NTFabiano]

Feeling stupid is a crucial part of science.

It means you're pushing into the unknown where real discoveries happen.

[Madison Conces, MD @MadisonConces]

@allisonoconn @CParkMD Aspirin is recommended in this setting based on the ALASCCA study.

https://t.co/VL780fPg7A